Tilray Medical has obtained a new license in Portugal, allowing the company to conduct quality tests on medical cannabis directly at its facility in Cantanhede, in the central part of the country. This decision is expected to speed up the time to market for products processed at its facility, reduce operating costs, and strengthen the company’s position in the European market.
Announced on October 13, 2026, this authorization was issued by INFARMED, the Portuguese National Authority for Medicines and Health Products. It covers the microbiological and physicochemical tests conducted at Tilray’s EU-GMP facility. These tests are part of the pharmaceutical quality control measures required for bringing cannabis-based medical products to market.
Bringing cannabis quality control under one roof
Until now, Tilray has relied in part on external laboratories to conduct these tests. This change is expected to shorten the time between the harvest, quality control, and distribution. It could also reduce expenses related to third-party laboratories while giving Tilray greater control over its production schedule.
Microbiological testing helps identify potential contamination, while physicochemical analyses help verify the characteristics of the products and their compliance with applicable pharmaceutical standards.
For companies that supply multiple countries, these procedures are an essential step before products can be placed on the market.
https://www.newsweed.fr/en/tilray-accelerates-operations-in-europe-licenses-in-portugal/
